Summit Therapeutics reports Q3 EPS (3c) vs (10c) last year

Reports Q3 aggregate cash and cash equivalents, restricted cash, short-term investments, and receivables on September 30 totaled $200.5M as compared to $654.7M on December 31, 2022. “Our cash, cash equivalents, restricted cash, and short-term investments on September 30 was $198.9M as compared to $648.6M on December 31, 2022. Accounts receivable and research and development tax credits receivable on September 30, were $1.6M as compared to $6.1M on December 31, 2022. Our short-term investments consist of U.S. treasury securities. Our current notes payable balance at September 30 was $100M, which is due in September 2024.”